Prana initiates Phase IIa Huntington disease trial

Reach2HD is a double blind placebo controlled study enrolling 100 patients with early to mid-stage Huntington Disease.

The six month study aims to demonstrate cognitive improvements as already demonstrated in a Phase IIa study in mild Alzheimer’s patients treated with PBT2.

The safety, functional, behavioral and motor benefits of the candidate will also be investigated in the Huntington patient population.

The trial is expected to be conducted in approximately 20 sites across the US and Australia.

Huntington disease is a complex and severely debilitating genetic, neurodegenerative disease, which causes incapacitation and death about 15-25 years after the onset.